


AMENDMENTS TO THE CLAIMS

Please cancel Claims 1-4 without prejudice and insert therefore new Claims 5-18. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-4 (Canceled)

5. (New) A method for the treatment of attention-deficit/hyperactivity disorder comprising administering to a subject in need thereof a therapeutically effective amount of the compound of formula I:



I

or a pharmaceutically acceptable salt thereof.

6. (New) The method of Claim 5 wherein the mesylate salt of the compound of formula I is administered to the subject.

7. (New) The method of Claim 5 wherein the subject is a human male.


8. (New) The method of Claim 7 wherein the subject is a human male aged 5-18 years.

9. (New) The method of Claim 5 wherein the attention-deficit/hyperactivity disorder is of the combined type.

10. (New) The method of Claim 5 wherein the attention-deficit/hyperactivity disorder is of the predominantly inattentive type.

11. (New) The method of Claim 5 wherein the attention-deficit/hyperactivity disorder is of the predominantly hyperactive-impulse type.

12. (New) A method for the prevention of attention-deficit/hyperactivity disorder comprising administering to a subject in need thereof a therapeutically effective amount of the compound of formula I:



I

or a pharmaceutically acceptable salt thereof.

13. (New) The method of Claim 12 wherein the mesylate salt of the compound of formula I is administered to the subject.

14. (New) The method of Claim 12 wherein the subject is a human male.

15. (New) The method of Claim 14 wherein the subject is a human male aged 5-18 years.

16. (New) The method of Claim 12 wherein the attention-deficit/hyperactivity disorder is of the combined type.

17. (New) The method of Claim 12 wherein the attention-deficit/hyperactivity disorder is of the predominantly inattentive type.

18. (New) The method of Claim 12 wherein the attention-deficit/hyperactivity disorder is of the predominantly hyperactive-impulse type.